- Home
- GBIO vs ATRA Comparison
GBIO vs ATRA Comparison
Compare GBIO & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBIO
- ATRA
- Stock Information
- Founded
- GBIO 2016
- ATRA 2012
- Country
- GBIO United States
- ATRA United States
- Employees
- GBIO N/A
- ATRA N/A
- Industry
- GBIO Biotechnology: Pharmaceutical Preparations
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GBIO Health Care
- ATRA Health Care
- Exchange
- GBIO Nasdaq
- ATRA Nasdaq
- Market Cap
- GBIO 35.2M
- ATRA 39.7M
- IPO Year
- GBIO 2020
- ATRA 2014
- Fundamental
- Price
- GBIO $0.51
- ATRA $6.86
- Analyst Decision
- GBIO Strong Buy
- ATRA Buy
- Analyst Count
- GBIO 2
- ATRA 6
- Target Price
- GBIO $6.50
- ATRA $25.70
- AVG Volume (30 Days)
- GBIO 386.8K
- ATRA 71.1K
- Earning Date
- GBIO 03-18-2025
- ATRA 03-07-2025
- Dividend Yield
- GBIO N/A
- ATRA N/A
- EPS Growth
- GBIO N/A
- ATRA N/A
- EPS
- GBIO N/A
- ATRA N/A
- Revenue
- GBIO $18,582,000.00
- ATRA $128,940,000.00
- Revenue This Year
- GBIO $212.74
- ATRA N/A
- Revenue Next Year
- GBIO N/A
- ATRA N/A
- P/E Ratio
- GBIO N/A
- ATRA N/A
- Revenue Growth
- GBIO 514.08
- ATRA 1404.02
- 52 Week Low
- GBIO $0.47
- ATRA $5.40
- 52 Week High
- GBIO $4.65
- ATRA $20.83
- Technical
- Relative Strength Index (RSI)
- GBIO 31.86
- ATRA 41.62
- Support Level
- GBIO $0.47
- ATRA $5.94
- Resistance Level
- GBIO $0.62
- ATRA $7.02
- Average True Range (ATR)
- GBIO 0.05
- ATRA 0.58
- MACD
- GBIO 0.01
- ATRA 0.07
- Stochastic Oscillator
- GBIO 24.10
- ATRA 52.36
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).